JUN and neoplasm: Engineering CAR-T cells to overexpress c-Jun (a typical AP-1 factor) increased CAR-T expansion, enhanced effector function, and reduced differentiation towards terminal exhaustion, resulting in a more potent anti-tumor effect [174].